Coronary risk factors and inflammation in patients with coronary artery disease and internal cardioverter defibrillator implants

International Journal of Cardiology

Volumn 112, Issue 1, 2006, Pages 72-79

  De Sutter, J ^a   Tavernier, R ^a   De Bacquer, D ^b   De Buyzere, M ^a   Van de Veire, N R ^a   Jordaens, L ^c   Matthys, K ^d   Bernard, D ^e   Langlois, M ^e   De Backer, G ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d PFIZER INC   (United States)

^e Department of Biochemistry ^*  (Belgium)

Author keywords

Coronary artery disease; Inflammation; Internal cardioverter defibrillator; Risk factors

Indexed keywords

HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY RISK; DEFIBRILLATOR; DIABETES MELLITUS; FEMALE; HUMAN; IMPLANT; INFLAMMATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; STATISTICAL ANALYSIS;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BELGIUM; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; DEFIBRILLATORS, IMPLANTABLE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GREECE; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPIDS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREVALENCE; PYRROLES; RESEARCH DESIGN; RISK FACTORS; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 33747344531     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.09.020     Document Type: Article

References (35)

1. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
2. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
3. Kadish A. Prophylactic defibrillator implantation-toward an evidence-based approach. N Engl J Med 352 (2005) 285-286
4. De Sutter J., Tavernier R., De Buyzere M., Jordaens L., and De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 36 (2000) 766-772
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
6. Sacks F.M., Pfeffer M.A., Moyé L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 355 (1996) 1001-1009
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
9. LaRosa J.C., Grundy S.M., Waters D.D., et al., for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
10. Mitchell L.B., Powell J.L., Gillis A.M., Kehl V., Hallstrom A.P., and and the AVID investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 42 (2003) 81-87
11. Chiu J.H., Abdelhadi R.H., Chung M.K., et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 95 (2005) 490-491
12. De Sutter J., Firsovaite V., and Tavernier R. Prevention of sudden death in patients with coronary artery disease: do lipid-lowering drugs play a role?. Prev Cardiol 4 (2002) 177-182
13. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 (2004) II2-II10
14. Libby P. Act local, act global. Inflammation and the multiplicity of "vulnerable" coronary plaques. J Am Coll Cardiol 45 (2005) 1600-1602
15. Ridker P.M., et al., for the PROVE IT-TIMI 22 investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
16. Nissen S.E., et al., for the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
17. Gregoratos G., Cheitlin M., Conill A., et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: executive summary. Circulation 97 (1998) 1325-1335
18. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rodgers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
19. Anavekar N.S., McMurray J.J.V., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 (2004) 1285-1295
20. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22 (2001) 554-572
21. Pyörälä K., Lehto S., De Bacquer D., et al., on behalf of the EUROASPIRE I and II group. Risk factor management in diabetic and non-diabetic coronary heart disease patients: findings from EUROASPIRE I and II Surveys. Diabetologia 47 (2004) 1257-1265
22. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
23. Mahon N.G., Blackstone E.H., Francis G.S., Starling R.C., Young J.B., and Lauer M.S. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic heart failure. J Am Coll Cardiol 40 (2002) 1106-1113
24. Wright R.S., Reeder G.S., Herzog C.A., et al. Acute myocardial infarction and renal dysfunction: a high risk combination. Ann Intern Med 137 (2002) 563-570
25. National Kidney Foundation. Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 Suppl 1 (2002) S1-S266
26. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 24 (2003) 1601-1610
27. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239 (Erratum, Circulation 2004;110:763.)
28. Horwich T.B., Hamilton M.A., MacLellan W.R., and Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8 (2002) 216-224
29. Rauchaus M., Clark A.L., Doehner W., et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42 (2003) 1933-1940
30. Fonarow G.C., and Horwich T.B. Cholesterol and mortality in heart failure: the bad gone good?. J Am Coll Cardiol 42 (2003) 1941-1943
31. Haramaki N., and Ikeda H. Statins for heart failure: a potential for new treatment. Cardiovasc Res 60 (2003) 217-219
32. Horwich T.B., Maclellan W.R., and Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004) 642-648
33. Krum H., and Mc Murray J.J. Statins and chronic heart failure: do we need a large-scale outcome trial?. J Am Coll Cardiol 39 (2002) 1567-1573
34. Hansson G.K. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
35. Pires L.A., Sethuraman B., Guduguntla V.D., Todd K.M., Yamasaki H., and Ravi S. Outcome of women versus men with ventricular tachyarrhythmias treated with the implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 13 (2002) 563-568